Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.

Otsu, Tomohisa; Inokawa, Yoshikuni; Takami, Hideki; Hayashi, Masamichi; Kurimoto, Keisuke; Tanaka, Nobutake; Tanaka, Haruyoshi; Shimizu, Dai; Hattori, Norifumi; Kanda, Mitsuro; Tanaka, Chie; Nakayama, Goro; Kodera, Yasuhiro

doi:10.21873/anticanres.15882

Record: found
Abstract: found
Article: not found

Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.

Author(s): Tomohisa Otsu ¹ , Yoshikuni Inokawa ² , Hideki Takami ¹ , Masamichi Hayashi ¹ , Keisuke Kurimoto ¹ , Nobutake Tanaka ¹ , Haruyoshi Tanaka ¹ , Dai Shimizu ¹ , Norifumi Hattori ¹ , Mitsuro Kanda ¹ , Chie Tanaka ¹ , Goro Nakayama ¹ , Yasuhiro Kodera ¹

Publication date (Electronic): Aug 2022

Journal: Anticancer research

Publisher: Anticancer Research USA Inc.

Keywords: FOLFIRINOX, Pancreatic cancer, nal-IRI, pegfilgrastim, peripheral neuropathy, second-line chemotherapy

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The regimen of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin (Nal-IRI/FL) was approved in Japan as second-line chemotherapy after gemcitabine-based treatment for pancreatic ductal adenocarcinoma (PDAC) in 2020. We examined the difference in outcome between patients treated with second-line folinic acid, fluorouracil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX) and those treated with nal-IRI/FL after first-line gemcitabine and nab-paclitaxel (GnP).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Anticancer Res

Title: Anticancer research

Publisher: Anticancer Research USA Inc.

ISSN (Electronic): 1791-7530

ISSN (Print): 0250-7005

Publication date (Electronic): Aug 2022

Volume: 42

Issue: 8

Affiliations

[1 ] Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.

[2 ] Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan yinokawa@med.nagoya-u.ac.jp.

Article

Publisher Item ID: 42/8/3889

DOI: 10.21873/anticanres.15882

PubMed ID: 35896232

SO-VID: e0b8ac7c-7807-446a-82c3-18c49a8ec189

History

Keywords: second-line chemotherapy,peripheral neuropathy,pegfilgrastim,nal-IRI,FOLFIRINOX,Pancreatic cancer

Data availability:

Keywords: second-line chemotherapy, peripheral neuropathy, pegfilgrastim, nal-IRI, FOLFIRINOX, Pancreatic cancer

Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.

Read this article at

Abstract

Related collections

Embodied Memory

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 376

Cited by 4